Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design

Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some clinicians have moved outside of evidence‐based...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuter, Stephanie E., Evans, Allan M., Ward, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363066/
https://www.ncbi.nlm.nih.gov/pubmed/30426719
http://dx.doi.org/10.1002/psp4.12364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363066/
https://www.ncbi.nlm.nih.gov/pubmed/30426719
http://dx.doi.org/10.1002/psp4.12364

Ejemplares similares